Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 761820, 13 pages
http://dx.doi.org/10.1155/2015/761820
Review Article

Peptide-Based Treatment: A Promising Cancer Therapy

Department of Gastroenterology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China

Received 26 September 2014; Accepted 14 December 2014

Academic Editor: Masha Fridkis-Hareli

Copyright © 2015 Yu-Feng Xiao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Iikuni, B. H. Hahn, and A. La Cava, “Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus,” Expert Opinion on Biological Therapy, vol. 9, no. 2, pp. 201–206, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Larché, “Peptide therapy for allergic diseases: basic mechanisms and new clinical approaches,” Pharmacology & Therapeutics, vol. 108, no. 3, pp. 353–361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L.-P. Boulet, “Allergen-derived T cell peptides and late asthmatic responses,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 1, pp. 2–3, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. P. Atamas, “Relief from within: a peptide therapy for fibrosis,” Science Translational Medicine, vol. 4, no. 136, Article ID 136fs16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Oh and M. Lee, “Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury,” Journal of Controlled Release, vol. 175, no. 1, pp. 25–35, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Nojiri, H. Hosoda, T. Tokudome et al., “Atrial natriuretic peptide inhibits lipopolysaccharide-induced acute lung injury,” Pulmonary Pharmacology & Therapeutics, vol. 29, no. 1, pp. 24–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. N. Francis and M. Larché, “Peptide-based vaccination: where do we stand?” Current Opinion in Allergy and Clinical Immunology, vol. 5, no. 6, pp. 537–543, 2005. View at Google Scholar
  8. M. A. Cheever and C. S. Higano, “PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine,” Clinical Cancer Research, vol. 17, no. 11, pp. 3520–3526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Takahashi, U. Toh, N. Iwakuma et al., “Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients,” Breast Cancer Research, vol. 16, no. 4, article R70, 2014. View at Publisher · View at Google Scholar
  10. R. Roy, D. Zurakowski, J. Wischhusen et al., “Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies,” British Journal of Cancer, vol. 111, no. 9, pp. 1772–1779, 2014. View at Publisher · View at Google Scholar
  11. X. B. Wang, Y. F. Li, H. M. Tian et al., “Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma,” BMC Cancer, vol. 14, no. 1, article 578, 2014. View at Publisher · View at Google Scholar
  12. N. Jiang, R. H. Xue, F. F. Bu, X. Tong, J. K. Qiang, and R. Liu, “Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 4120–4127, 2014. View at Google Scholar
  13. Z.-X. Zheng, Y. Sun, Z.-D. Bu et al., “Intestinal stem cell marker LGR5 expression during gastric carcinogenesis,” World Journal of Gastroenterology, vol. 19, no. 46, pp. 8714–8721, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Lu, B. Zhou, G. Q. Gao, D. Li, X. D. Liu, and B. Huang, “Clinical significance in combined detection of serum pepsinogen I, pepsinogen II and carbohydrate antigen 242 in gastric cancer,” Hepatogastroenterology, vol. 61, no. 129, pp. 255–258, 2014. View at Google Scholar
  15. S. E. Mcgrath, A. Michael, R. Morgan, and H. Pandha, “EN2: a novel prostate cancer biomarker,” Biomarkers in Medicine, vol. 7, no. 6, pp. 893–901, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Li, K. Nichols, C.-A. Nathan, and Y. Zhao, “Mitochondrial uncoupling protein 2 is up-regulated in human head and neck, skin, pancreatic, and prostate tumors,” Cancer Biomarkers, vol. 13, no. 5, pp. 377–383, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Boku, “HER2-positive gastric cancer,” Gastric Cancer, vol. 17, no. 1, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. J. S. Zanetti, D. F. Soave, J. P. Oliveira-Costa et al., “The role of tumor hypoxia in MUC1-positive breast carcinomas,” Virchows Archiv, vol. 459, no. 4, pp. 367–375, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Albrethsen, C. H. Møller, J. Olsen, H. Raskov, and S. Gammeltoft, “Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer,” European Journal of Cancer, vol. 42, no. 17, pp. 3057–3064, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Bloch, Y. Kam, E. Yavin et al., “The relative roles of charge and a recognition peptide in luminal targeting of colorectal cancer by fluorescent polyacrylamide,” European Journal of Pharmaceutical Sciences, vol. 47, no. 5, pp. 904–913, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. S. Comstock, D. Xu, K. Hortos et al., “Association of insulin-related serum factors with colorectal polyp number and type in adult males,” Cancer Epidemiology, Biomarkers & Prevention, vol. 23, no. 9, pp. 1843–1851, 2014. View at Google Scholar
  22. W. Wang, S. Guan, S. Sun et al., “Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer,” Tumor Biology, vol. 35, no. 5, pp. 4901–4905, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Zhang, X. Li, X. Zhang, Y. Yang, Z. Feng, and X. Liu, “Association of serum hemoglobin A1c, C-peptide and insulin-like growth factor-1 levels with the occurrence and development of lung cancer,” Molecular Clinical Oncology, vol. 2, no. 4, pp. 506–508, 2014. View at Google Scholar
  24. M. J. McGuire, B. P. Gray, S. Li et al., “Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer,” Scientific Reports, vol. 4, article 4480, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. D. de Costa, I. Broodman, W. Calame et al., “Peptides from the variable region of specific antibodies are shared among lung cancer patients,” PLoS ONE, vol. 9, no. 5, Article ID e96029, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Wang, L. Chen, K. Pu, and Y. Zhu, “Identification of stem-like cells in non-small cell lung cancer cells with specific peptides,” Cancer Letters, vol. 351, no. 1, pp. 100–107, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Nishida, S. Koido, Y. Takeda et al., “Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer,” Journal of Immunotherapy, vol. 37, no. 2, pp. 105–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Suzuki, S. Hazama, T. Ueno et al., “A phase i clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer,” Journal of Immunotherapy, vol. 37, no. 1, pp. 36–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Staff, F. Mozaffari, J.-E. Frodin, H. Mellstedt, and M. Liljefors, “Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients,” International Journal of Oncology, vol. 45, no. 3, pp. 1293–1303, 2014. View at Publisher · View at Google Scholar
  30. T. Masuzawa, Y. Fujiwara, K. Okada et al., “Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer,” International Journal of Oncology, vol. 41, no. 4, pp. 1297–1304, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Ishikawa, M. Imano, O. Shiraishi et al., “Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer,” Gastric Cancer, vol. 17, no. 1, pp. 173–180, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. J. M. S. Saif, J. Vadakekolathu, S. S. Rane et al., “Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice,” European Journal of Immunology, vol. 44, no. 4, pp. 994–1004, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Mansourian, A. Badiee, S. A. Jalali et al., “Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN,” Immunology Letters, vol. 162, no. 1, part A, pp. 87–93, 2014. View at Publisher · View at Google Scholar
  34. J. Ohtake, T. Ohkuri, Y. Togashi, H. Kitamura, K. Okuno, and T. Nishimura, “Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine,” Immunology Letters, vol. 161, no. 1, pp. 20–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. E. A. Mittendorf, G. T. Clifton, J. P. Holmes et al., “Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients,” Annals of Oncology, vol. 25, no. 9, pp. 1735–1742, 2014. View at Publisher · View at Google Scholar
  36. E. Y. Gil, U. H. Jo, H. J. Lee et al., “Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice,” Breast Cancer Research and Treatment, vol. 147, no. 1, pp. 69–80, 2014. View at Publisher · View at Google Scholar
  37. A. Serafino, N. Moroni, R. Psaila et al., “Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1822, no. 6, pp. 1004–1018, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. Z. J. Li, W. K. K. Wu, S. S. M. Ng et al., “A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery,” Journal of Controlled Release, vol. 148, no. 3, pp. 292–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Wang, M. Zhao, Y.-R. Liu et al., “Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature,” Biomaterials, vol. 35, no. 4, pp. 1215–1226, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Takahashi, M. Okamoto, S. Shimodaira et al., “Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers,” European Journal of Cancer, vol. 49, no. 4, pp. 852–859, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Kotsakis, E. Papadimitraki, E. K. Vetsika et al., “A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide,” Lung Cancer, vol. 86, no. 1, pp. 59–66, 2014. View at Publisher · View at Google Scholar
  42. A. Ahsa, S. G. Ramanand, I. L. Bergin et al., “Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts,” Neoplasia, vol. 16, no. 2, pp. 105–114, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. A. B. Sigalov, “A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock,” International Immunopharmacology, vol. 21, no. 1, pp. 208–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Chittasupho, K. Lirdprapamongkol, P. Kewsuwan, and N. Sarisuta, “Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 88, no. 2, pp. 529–538, 2014. View at Publisher · View at Google Scholar
  45. X. Wang, C. Yang, Y. Zhang, X. Zhen, W. Wu, and X. Jiang, “Delivery of platinum(IV) drug to subcutaneous tumor and lung metastasis using bradykinin-potentiating peptide-decorated chitosan nanoparticles,” Biomaterials, vol. 35, no. 24, pp. 6439–6453, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Y. Guan, X. Luan, J. R. Xu et al., “Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis,” Biomaterials, vol. 35, no. 9, pp. 3060–3070, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Noguchi, F. Moriya, S. Suekane et al., “A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time,” BMC Cancer, vol. 13, article 613, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Fenoglio, P. Traverso, A. Parodi et al., “A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer,” Cancer Immunology, Immunotherapy, vol. 62, no. 6, pp. 1041–1052, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Shariat, A. Badiee, M. R. Jaafari, and S. A. Mortazavi, “Optimization of a method to prepare liposomes containing HER2/Neu-derived peptide as a vaccine delivery system for breast cancer,” Iranian Journal of Pharmaceutical Research, vol. 13, pp. 15–25, 2014. View at Google Scholar · View at Scopus
  50. D. A. L. Vital, E. G. de Mejía, V. P. Dia, and G. Loarca-Piña, “Peptides in common bean fractions inhibit human colorectal cancer cells,” Food Chemistry, vol. 157, pp. 347–355, 2014. View at Publisher · View at Google Scholar
  51. S. Inoda, R. Morita, Y. Hirohashi et al., “The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma,” Experimental and Molecular Pathology, vol. 90, no. 1, pp. 55–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Hazama, H. Takenouchi, R. Tsunedomi et al., “Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer,” Anticancer Research, vol. 34, no. 8, pp. 4201–4205, 2014. View at Google Scholar
  53. K. Okuno, F. Sugiura, K. Inoue, and Y. Sukegawa, “Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer,” Anticancer Research, vol. 34, no. 6, pp. 3045–3052, 2014. View at Google Scholar
  54. S. J. Rayaprolu, N. S. Hettiarachchy, P. Chen, A. Kannan, and A. Mauromostakos, “Peptides derived from high oleic acid soybean meals inhibit colon, liver and lung cancer cell growth,” Food Research International, vol. 50, no. 1, pp. 282–288, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. J. M. Conlon, M. Prajeep, M. Mechkarska et al., “Peptides with in vitro anti-tumor activity from the venom of the Eastern green mamba, Dendroaspis angusticeps (Elapidae),” Journal of Venom Research, vol. 5, pp. 16–21, 2014. View at Google Scholar
  56. R. E. Schoen, “The case for population-based screening for colorectal cancer,” Nature Reviews Cancer, vol. 2, no. 1, pp. 65–70, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Hazama, Y. Nakamura, H. Takenouchi et al., “A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome,” Journal of Translational Medicine, vol. 12, no. 1, article 63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Früh, D. de Ruysscher, S. Popat, L. Crinò, S. Peters, and E. Felip, “Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 24, supplement 6, pp. vi99–vi105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. T. J. McDonald, M. A. Ghatei, S. R. Bloom et al., “A qualitative comparison of canine plasma gastroenteropancreatic hormone responses to bombesin and the porcine gastrin-releasing peptide (GRP),” Regulatory Peptides, vol. 2, no. 5, pp. 293–304, 1981. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Gniazdowska, P. Koźmiński, K. Bańkowski, and P. Ochman, “99mTc-labeled vasopressin peptide as a radiopharmaceutical for small-cell lung cancer (SCLC) diagnosis,” Journal of Medicinal Chemistry, vol. 57, no. 14, pp. 5986–5994, 2014. View at Publisher · View at Google Scholar
  62. Z. H. Hong, Y. Z. Shi, Z. L. Liu, X. L. Zhou, Y. Yang, and J. Tang, “Preliminary radioimmunoimaging and biodistribution of 131iodine-labeled single-chain antibody fragment against progastrin-releasing peptide (31–98) in small cell lung cancer xenografts,” Chinese Medical Journal, vol. 127, no. 11, pp. 2007–2011, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Takahara, S. Koido, M. Ito et al., “Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-speciWc T-cell-mediated antitumor immune response,” Cancer Immunology, Immunotherapy, vol. 60, no. 9, pp. 1289–1297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. M. L. Rothenberg, M. J. Moore, M. C. Cripps et al., “A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer,” Annals of Oncology, vol. 7, no. 4, pp. 347–353, 1996. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Parmiani, C. Castelli, P. Dalerba et al., “Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?” Journal of the National Cancer Institute, vol. 94, no. 11, pp. 805–818, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. F. M. Marincola, E. M. Jaffee, D. J. Hicklin, and S. Ferrone, “Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance,” Advances in Immunology, vol. 74, pp. 181–273, 2000. View at Google Scholar · View at Scopus
  68. L. Gao, I. Bellantuono, A. Elsässer et al., “Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1,” Blood, vol. 95, no. 7, pp. 2198–2203, 2000. View at Google Scholar · View at Scopus
  69. A. M. Storniolo, S. R. Allerheiligen, and H. L. Pearce, “Preclinical, pharmacologic, and phase I studies of gemcitabine,” Seminars in Oncology, vol. 24, no. 2, supplement 7, pp. S7-2–S7-7, 1997. View at Google Scholar · View at Scopus
  70. A. K. Nowak, B. W. S. Robinson, and R. A. Lake, “Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy,” Cancer Research, vol. 62, no. 8, pp. 2353–2358, 2002. View at Google Scholar · View at Scopus
  71. L. Rettig, S. Seidenberg, I. Parvanova, P. Samaras, A. Knuth, and S. Pascolo, “Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells,” International Journal of Cancer, vol. 129, no. 4, pp. 832–838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. A. K. Nowak, R. A. Lake, A. L. Marzo et al., “Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells,” The Journal of Immunology, vol. 170, no. 10, pp. 4905–4913, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Ramakrishnan, D. Assudani, S. Nagaraj et al., “Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice,” The Journal of Clinical Investigation, vol. 120, no. 4, pp. 1111–1124, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. E. Kawakami, R. S. Machado, S. K. Ogata, and M. Langner, “Decrease in prevalence of Helicobacter pylori infection during a 10-year period in Brazilian children,” Arquivos de Gastroenterologia, vol. 45, no. 2, pp. 147–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Ohtsu, “Current status and future prospects of chemotherapy for metastatic gastric cancer: a review,” Gastric Cancer, vol. 8, no. 2, pp. 95–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Clauss, “Molecular biology of the VEGF and the VEGF receptor family,” Seminars in Thrombosis and Hemostasis, vol. 26, no. 5, pp. 561–569, 2000. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Ishizaki, T. Tsunoda, S. Wada, M. Yamauchi, M. Shibuya, and H. Tahara, “Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1,” Clinical Cancer Research, vol. 12, no. 19, pp. 5841–5849, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Prewett, J. Huber, Y. Li et al., “Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors,” Cancer Research, vol. 59, no. 20, pp. 5209–5218, 1999. View at Google Scholar · View at Scopus
  79. N. Ferrara, H.-P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Zhang, Z. Zhang, X. Zhang, X. Gao, K. H. Kernstine, and L. Zhong, “Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma,” Biomarkers, vol. 17, no. 4, pp. 372–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. N. Ishikawa, A. Takano, W. Yasui et al., “Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas,” Cancer Research, vol. 67, no. 24, pp. 11601–11611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Iwahashi, M. Katsuda, M. Nakamori et al., “Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma,” Cancer Science, vol. 101, no. 12, pp. 2510–2517, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. A. L. Potosky, B. A. Miller, P. C. Albertsen, and B. S. Kramer, “The role of increasing detection in the rising incidence of prostate cancer,” The Journal of the American Medical Association, vol. 273, no. 7, pp. 548–552, 1995. View at Publisher · View at Google Scholar · View at Scopus
  84. E. S. Antonarakis and M. A. Eisenberger, “Expanding treatment options for metastatic prostate cancer,” The New England Journal of Medicine, vol. 364, no. 21, pp. 2055–2058, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. P. W. Kantoff, C. S. Higano, N. D. Shore et al., “Sipuleucel-T immunotherapy for castration-resistant prostate cancer,” The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Itoh and A. Yamada, “Personalized peptide vaccines: a new therapeutic modality for cancer,” Cancer Science, vol. 97, no. 10, pp. 970–976, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Sasada, A. Yamada, M. Noguchi, and K. Itoh, “Personalized peptide vaccine for treatment of advanced cancer,” Current Medicinal Chemistry, vol. 21, no. 21, pp. 2332–2345, 2014. View at Publisher · View at Google Scholar
  88. T. Sasada, M. Noguchi, A. Yamada, and K. Itoh, “Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer,” Human Vaccines & Immunotherapeutics, vol. 8, no. 9, pp. 1309–1313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Yamada, T. Sasada, M. Noguchi, and K. Itoh, “Next-generation peptide vaccines for advanced cancer,” Cancer Science, vol. 104, no. 1, pp. 15–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. F. M. Speetjens, P. J. K. Kuppen, M. J. P. Welters et al., “Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer,” Clinical Cancer Research, vol. 15, no. 3, pp. 1086–1095, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. R. L. Metheringham, V. A. Pudney, B. Gunn, M. Towey, I. Spendlove, and L. G. Durrant, “Antibodies designed as effective cancer vaccines,” mAbs, vol. 1, no. 1, pp. 71–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. L. G. Durrant, V. A. Pudney, and I. Spendlove, “Using monoclonal antibodies to stimulate antitumor cellular immunity,” Expert Review of Vaccines, vol. 10, no. 7, pp. 1093–1106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. C. A. Parise and V. Caggiano, “Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000–2010,” BMC Cancer, vol. 13, article 449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. C. Desantis, J. Ma, L. Bryan, and A. Jemal, “Breast cancer statistics, 2013,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 52–62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. E. Mohit, A. Hashemi, and M. Allahyari, “Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines,” Expert Review of Clinical Immunology, vol. 10, no. 7, pp. 927–961, 2014. View at Google Scholar
  96. S. E. Wright, “Immunotherapy of breast cancer,” Expert Opinion on Biological Therapy, vol. 12, no. 4, pp. 479–490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Dhillon, “Trastuzumab emtansine: a review of its use in patients with her2-positive advanced breast cancer previously treated with trastuzumab-based therapy,” Drugs, vol. 74, no. 6, pp. 675–686, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. L. Amiri-Kordestani, G. M. Blumenthal, Q. C. Xu et al., “FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer,” Clinical Cancer Research, vol. 20, no. 17, pp. 4436–4441, 2014. View at Publisher · View at Google Scholar
  99. L. Novellino, C. Castelli, and G. Parmiani, “A listing of human tumor antigens recognized by T cells: March 2004 update,” Cancer Immunology, Immunotherapy, vol. 54, no. 3, pp. 187–207, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. G. J. Morris, S. Naidu, A. K. Topham et al., “Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the national cancer institute's surveillance, epidemiology, and end results database,” Cancer, vol. 110, no. 4, pp. 876–884, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. B. D. Lehmann, J. A. Bauer, X. Chen et al., “Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies,” The Journal of Clinical Investigation, vol. 121, no. 7, pp. 2750–2767, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. C. Wang, Y. Zhuang, Y. Zhang et al., “Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells,” Vaccine, vol. 30, no. 32, pp. 4790–4799, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. W. Yan, W. Chen, and L. Huang, “Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines,” Molecular Immunology, vol. 44, no. 15, pp. 3672–3681, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Karkada, N. L. Berinstein, and M. Mansour, “Therapeutic vaccines and cancer: focus on DPX-0907,” Biologics: Targets and Therapy, vol. 8, pp. 27–38, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  106. S. K. Bhutia and T. K. Maiti, “Targeting tumors with peptides from natural sources,” Trends in Biotechnology, vol. 26, no. 4, pp. 210–217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. K. Fernald and M. Kurokawa, “Evading apoptosis in cancer,” Trends in Cell Biology, vol. 23, no. 12, pp. 620–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. W. Huang, J. Seo, S. B. Willingham et al., “Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity,” PLoS ONE, vol. 9, no. 2, Article ID e90397, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. D. Amit and A. Hochberg, “Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences,” Journal of Translational Medicine, vol. 8, article 134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. D. D. Wu, Y. F. Gao, Y. M. Qi, L. X. Chen, Y. F. Ma, and Y. Z. Li, “Peptide-based cancer therapy: opportunity and challenge,” Cancer Letters, vol. 351, no. 1, pp. 13–22, 2014. View at Publisher · View at Google Scholar
  111. M. Trepel, R. Pasqualini, and W. Arap, “Screening phage-display Peptide libraries for vascular targeted peptides,” in Methods in Enzymology, vol. 445 of Angiogenesis: In Vivo Systems, Part B, chapter 4, pp. 83–106, Elsevier, 2008. View at Publisher · View at Google Scholar
  112. N. D'Onofrio, M. Caraglia, A. Grimaldi et al., “Vascular-homing peptides for targeted drug delivery and molecular imaging: meeting the clinical challenges,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1846, no. 1, pp. 1–12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Shadidi and M. Sioud, “Selective targeting of cancer cells using synthetic peptides,” Drug Resistance Updates, vol. 6, no. 6, pp. 363–371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. S. M. Farkhani, A. Valizadeh, H. Karami, S. Mohammadi, N. Sohrabi, and F. Badrzadeh, “Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules,” Peptides, vol. 57, pp. 78–94, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Bolhassani, “Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1816, no. 2, pp. 232–246, 2011. View at Google Scholar · View at Scopus
  116. F.-S. Kao, Y.-R. Pan, R.-Q. Hsu, and H.-M. Chen, “Efficacy verification and microscopic observations of an anticancer peptide, CB1a, on single lung cancer cell,” Biochimica et Biophysica Acta—Biomembranes, vol. 1818, no. 12, pp. 2927–2935, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Beck, J. E. Gambee, C. A. Bohan, and H. P. Bächinger, “The C-terminal domain of cartilage matrix protein assembles into a triple-stranded α-helical coiled-coil structure,” Journal of Molecular Biology, vol. 256, no. 5, pp. 909–923, 1996. View at Publisher · View at Google Scholar · View at Scopus
  118. L. Q. Liu and Y. B. Miao, “Metastatic melanoma targeting property of a novel Tc-99m-labeled HYNIC-conjugated lactam bridge-cyclized alpha-MSH peptide,” Nuclear Medicine and Biology, vol. 41, no. 7, p. 622, 2014. View at Publisher · View at Google Scholar
  119. F. E. González, M. Ramírez, E. B. Allerbring et al., “Melanocortin 1 receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients,” Immunobiology, vol. 219, no. 3, pp. 189–197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. E. Vacas, A. M. Bajo, A. V. Schally, M. Sánchez-Chapado, J. C. Prieto, and M. J. Carmena, “Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma,” Molecular and Cellular Endocrinology, vol. 365, no. 2, pp. 212–222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  121. K. Yoshimura, T. Minami, M. Nozawa, and H. Uemura, “Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma,” British Journal of Cancer, vol. 108, no. 6, pp. 1260–1266, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Rausch, S. Kruck, A. Stenzl, and J. Bedke, “IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy,” Future Oncology, vol. 10, no. 6, pp. 937–948, 2014. View at Publisher · View at Google Scholar
  123. Y. Liu, X. Cui, Y.-E. Sun et al., “Intrathecal injection of the peptide Myr-NR2B9c attenuates bone cancer pain via perturbing N-methyl-D-aspartate receptor-PSD-95 protein interactions in mice,” Anesthesia & Analgesia, vol. 118, no. 6, pp. 1345–1354, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. Z. Xu, S. Ramishetti, Y.-C. Tseng, S. Guo, Y. Wang, and L. Huang, “Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis,” Journal of Controlled Release, vol. 172, no. 1, pp. 259–265, 2013. View at Publisher · View at Google Scholar · View at Scopus
  125. Z. J. Li and C. H. Cho, “Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery,” Journal of Translational Medicine, vol. 10, article S1, 2012. View at Google Scholar · View at Scopus
  126. E. Ruoslahti, S. N. Bhatia, and M. J. Sailor, “Targeting of drugs and nanoparticles to tumors,” The Journal of Cell Biology, vol. 188, no. 6, pp. 759–768, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. J. Enbäck and P. Laakkonen, “Tumour-homing peptides: tools for targeting, imaging and destruction,” Biochemical Society Transactions, vol. 35, no. 4, pp. 780–783, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. A. J. T. George, L. Lee, and C. Pitzalis, “Isolating ligands specific for human vasculature using in vivo phage selection,” Trends in Biotechnology, vol. 21, no. 5, pp. 199–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. F. Aranda, E. Vacchelli, A. Eggermont et al., “Trial watch: peptide vaccines in cancer therapy,” OncoImmunology, vol. 2, no. 12, Article ID e26621, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. M. Mohme, M. C. Neidert, L. Regli, M. Weller, and R. Martin, “Immunological challenges for peptide-based immunotherapy in glioblastoma,” Cancer Treatment Reviews, vol. 40, no. 2, pp. 248–258, 2014. View at Publisher · View at Google Scholar · View at Scopus
  131. R. Takahashi, U. Toh, N. Iwakuma et al., “Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients,” Breast Cancer Research, vol. 16, no. 4, article R70, 2014. View at Publisher · View at Google Scholar
  132. D. Valmori, J.-F. Fonteneau, C. M. Lizana et al., “Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues,” The Journal of Immunology, vol. 160, no. 4, pp. 1750–1758, 1998. View at Google Scholar · View at Scopus